The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review

Purpose Serous adenocarcinoma (uterine serous carcinoma – USC) is a rare and aggressive histologic subtype of endometrial cancer, with a high-rate of recurrence and poor prognosis. The adjuvant treatment for stage I patients is unclear. The purpose of this study was to evaluate the outcomes of stage I USC treated exclusively with chemotherapy plus vaginal brachytherapy (VBT). Material and methods A systematic research using PubMed, Scopus, and Cochrane library was conducted to identify full articles evaluating the efficacy of VBT in patients with stage I USC. A search in ClinicalTrials.gov was performed in order to detect ongoing or recently completed trials, and in PROSPERO for searching ongoing or recently completed systematic reviews. Results All studies were retrospective and 364 of evaluated patients were found. The average local control was 97.5% (range, 91-100%), the disease free-survival was 88% (range, 82-94%), the overall survival was 93% (range, 72-100%), the specific cancer survival was 89.4% (range, 84.8-94%), and the G3-G4 toxicity was 0-8%. Conclusions These data support the concept that in adequately selected patients, VBT alone may be a suitable radiotherapy technique in women with stage I USC who underwent surgical staging and received adjuvant chemotherapy.

[1]  Jae-Weon Kim,et al.  Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Giovagnoni,et al.  Current state of interventional radiotherapy (brachytherapy) education in Italy: results of the INTERACTS survey , 2019, Journal of contemporary brachytherapy.

[3]  A. Barcellini,et al.  Vaginal toxicity after high-dose-rate endovaginal brachytherapy: 20 years of results , 2018, Journal of contemporary brachytherapy.

[4]  G. Pond,et al.  Outcomes of Adjuvant Therapy for Stage IA Serous Endometrial Cancer , 2018, Cureus.

[5]  V. Valentini,et al.  EROS study: evaluation between high-dose-rate and low-dose-rate vaginal interventional radiotherapy (brachytherapy) in terms of overall survival and rate of stenosis , 2018, Journal of contemporary brachytherapy.

[6]  F. Vianello,et al.  A new standardized data collection system for interdisciplinary thyroid cancer management: Thyroid COBRA. , 2018, European journal of internal medicine.

[7]  R. Autorino,et al.  A national survey of AIRO (Italian Association of Radiation Oncology) brachytherapy (Interventional Radiotherapy) study group , 2018, Journal of contemporary brachytherapy.

[8]  V. Valentini,et al.  ENT COBRA ONTOLOGY: the covariates classification system proposed by the Head & Neck and Skin GEC-ESTRO Working Group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy) , 2018, Journal of contemporary brachytherapy.

[9]  J. Kwon,et al.  The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis. , 2018, Gynecologic oncology.

[10]  M. Shruthi,et al.  Combined external beam radiotherapy and vaginal brachytherapy versus vaginal brachytherapy in stage I, intermediate- and high-risk cases of endometrium carcinoma , 2018, Journal of contemporary brachytherapy.

[11]  V. Valentini,et al.  Is an Interventional Oncology Center an advantage in the service of cancer patients or in the education? The Gemelli Hospital and INTERACTS experience , 2017, Journal of contemporary brachytherapy.

[12]  L. Azario,et al.  Nomogram for predicting radiation maculopathy in patients treated with Ruthenium-106 plaque brachytherapy for uveal melanoma , 2017, Journal of contemporary brachytherapy.

[13]  M. Elshaikh,et al.  External pelvic and vaginal irradiation vs. vaginal irradiation alone as postoperative therapy in women with early stage uterine serous carcinoma: Results of a National Cancer Database analysis. , 2017, Brachytherapy.

[14]  Vincenzo Valentini,et al.  ENT COBRA (Consortium for Brachytherapy Data Analysis): interdisciplinary standardized data collection system for head and neck patients treated with interventional radiotherapy (brachytherapy) , 2016, Journal of contemporary brachytherapy.

[15]  M. Köbel,et al.  Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers. , 2015, Gynecologic oncology.

[16]  J. Carrier,et al.  Adjuvant Chemotherapy and Vaginal Vault Brachytherapy With or Without Pelvic Radiotherapy for Stage 1 Papillary Serous or Clear Cell Endometrial Cancer , 2015, International Journal of Gynecologic Cancer.

[17]  S. Waggoner,et al.  Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma , 2015 .

[18]  S. Waggoner,et al.  Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study. , 2015, Gynecologic oncology.

[19]  R. Den,et al.  Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer , 2014, Journal of contemporary brachytherapy.

[20]  J. Debus,et al.  Survival of women with clear cell and papillary serous endometrial cancer after adjuvant radiotherapy , 2014, Radiation oncology.

[21]  V. Strnad,et al.  Intraluminal brachytherapy in oesophageal cancer: defining its role and introducing the technique , 2014, Journal of contemporary brachytherapy.

[22]  R. Barakat,et al.  Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy. , 2013, Gynecologic oncology.

[23]  M. Birrer,et al.  Uterine papillary serous cancer: a review of the literature. , 2012, Gynecologic oncology.

[24]  R. Barakat,et al.  Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. , 2012, Gynecologic oncology.

[25]  A. Secord,et al.  An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). , 2009, Gynecologic oncology.

[26]  P. Gehrig,et al.  Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. , 2009, Gynecologic oncology.

[27]  L. Havrilesky,et al.  Platinum/taxane‐based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma , 2009, Cancer.

[28]  D. Cella,et al.  A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. , 2009, Gynecologic oncology.

[29]  R. Naumann.  Uterine papillary serous carcinoma: State of the state , 2008, Current oncology reports.

[30]  V. Valentini,et al.  Videoconferencing to enhance the integration between clinical medicine and teaching: a feasibility study. , 2008, Tumori.

[31]  D. Mutch,et al.  Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. , 2008, Gynecologic oncology.

[32]  M. Carey,et al.  Is adjuvant therapy necessary for Stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging? , 2007, International Journal of Gynecologic Cancer.

[33]  M. Hendrickson,et al.  Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers , 2006, British Journal of Cancer.

[34]  T. Roy,et al.  Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. , 2006, Gynecologic oncology.

[35]  P. Boyle,et al.  Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. , 2004, Gynecologic oncology.

[36]  R. Burger,et al.  Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. McDonald,et al.  High-dose rate brachytherapy for Stage I/II papillary serous or clear cell endometrial cancer. , 2004, Gynecologic oncology.

[38]  R. Bentley,et al.  Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  R. Burger,et al.  Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  R. Broaddus,et al.  Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. , 2003, Gynecologic oncology.

[41]  R. Burger,et al.  Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  A. Mundt,et al.  Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. , 2003, International journal of radiation oncology, biology, physics.

[43]  V. Abeler,et al.  Clear-cell and papillary serous cancer: treatment options. , 2001, Best practice & research. Clinical obstetrics & gynaecology.

[44]  E. Trimble,et al.  Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease. , 2001, Gynecologic oncology.

[45]  M. Maiman,et al.  Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. , 1997, Gynecologic oncology.

[46]  J. Nicklin,et al.  Endometrial papillary serous carcinoma: patterns of spread and treatment. , 1996, Clinical obstetrics and gynecology.

[47]  M. R. Smith,et al.  Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma. , 1994, American journal of obstetrics and gynecology.

[48]  R. Lotocki,et al.  Papillary serous adenocarcinoma of the endometrium. , 1986, Obstetrics and gynecology.

[49]  R. Kempson,et al.  Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma , 1982, The American journal of surgical pathology.

[50]  R. Iezzi,et al.  Interventional Oncology: Should Interventional Radiotherapy (Brachytherapy) be Integrated into Modern Treatment Procedures? , 2019, Turkish Journal of Oncology.

[51]  D. Gaffney,et al.  American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review. , 2017, Brachytherapy.

[52]  A. Tinker,et al.  Population-based treatment and outcomes of Stage I uterine serous carcinoma. , 2014, Gynecologic oncology.

[53]  A. Mariani,et al.  The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer. , 2013, International journal of radiation oncology, biology, physics.

[54]  M. Siddiqui,et al.  Clinical outcomes of adjuvant chemotherapy and vaginal brachytherapy with or without pelvic radiation for surgical stage I-II uterine serous carcinoma. , 2012, European journal of gynaecological oncology.

[55]  L. Wilson,et al.  Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy. , 1998, International journal of radiation oncology, biology, physics.

[56]  S. Lauchlan.  Tubal (serous) carcinoma of the endometrium. , 1981, Archives of pathology & laboratory medicine.